rs149715830
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_181882.3(PRX):c.1574T>C(p.Val525Ala) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00082 in 1,608,936 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_181882.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PRX | NM_181882.3 | c.1574T>C | p.Val525Ala | missense_variant | 7/7 | ENST00000324001.8 | NP_870998.2 | |
PRX | NM_001411127.1 | c.1859T>C | p.Val620Ala | missense_variant | 7/7 | NP_001398056.1 | ||
PRX | XM_017027047.2 | c.1472T>C | p.Val491Ala | missense_variant | 4/4 | XP_016882536.1 | ||
PRX | NM_020956.2 | c.*1779T>C | 3_prime_UTR_variant | 6/6 | NP_066007.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00128 AC: 195AN: 151838Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000570 AC: 143AN: 250708Hom.: 0 AF XY: 0.000560 AC XY: 76AN XY: 135612
GnomAD4 exome AF: 0.000772 AC: 1125AN: 1456982Hom.: 2 Cov.: 36 AF XY: 0.000851 AC XY: 617AN XY: 724740
GnomAD4 genome AF: 0.00128 AC: 195AN: 151954Hom.: 0 Cov.: 32 AF XY: 0.00117 AC XY: 87AN XY: 74292
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:4
Likely benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jun 01, 2023 | BP4 - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The PRX p.Val525Ala variant was identified in 3 of 950 proband chromosomes (frequency: 0.0032) from individuals or families with Inherited Peripheral Neuropathies and was not identified in 4492 control chromosomes from healthy individuals (Schabhüttl_2014_PMID: 24627108; Antoniadi_2015_PMID: 26392352). The variant was also identified in dbSNP (ID: rs149715830) and in ClinVar where there are conflicting interpretations of pathogenicity for Charcot-Marie-Tooth disease type 4 from five submitters: 4x uncertain significance (Invitae, Illumina Clinical Services Laboratory, EGL Genetic Diagnostics, and Praxis fuer Humangenetik Tuebingen) and 1x likely benign by GeneDx. The variant was identified in control databases in 193 of 282028 chromosomes at a frequency of 0.000684 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European (non-Finnish) in 160 of 128602 chromosomes (freq: 0.001244), Other in 7 of 7216 chromosomes (freq: 0.00097), European (Finnish) in 12 of 25114 chromosomes (freq: 0.000478), African in 8 of 24778 chromosomes (freq: 0.000323), Ashkenazi Jewish in 2 of 10336 chromosomes (freq: 0.000194), Latino in 3 of 35432 chromosomes (freq: 0.000085) and South Asian in 1 of 30616 chromosomes (freq: 0.000033); it was not observed in the East Asian population. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, and GeneSplicer) do not predict a difference in splicing. The p.Val525 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, AlignGVGD, BLOSUM, and MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2024 | PRX: BP4 - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Oct 29, 2020 | This variant is associated with the following publications: (PMID: 24627108, 26392352, 32376792) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 01, 2018 | - - |
Charcot-Marie-Tooth disease Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Molecular Genetics Laboratory, London Health Sciences Centre | - | - - |
Uncertain significance, no assertion criteria provided | literature only | Inherited Neuropathy Consortium | - | - - |
not specified Uncertain:1Benign:1
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jul 05, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 12, 2024 | Variant summary: PRX c.1574T>C (p.Val525Ala) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00057 in 250708 control chromosomes, predominantly at a frequency of 0.001 within the Non-Finnish European subpopulation in the gnomAD database. c.1574T>C has been reported in the literature in several individuals affected with Inherited peripheral neuropathies or undertaking neuroinflammation/CMT panel testing, without strong evidence for causality (example, McCreary_2019, Schabhuttl_2014, Volodarsky_2021). These report(s) do not provide unequivocal conclusions about association of the variant with PRX-Related Disorders. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 31664448, 24627108, 32376792). ClinVar contains an entry for this variant (Variation ID: 242179). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Charcot-Marie-Tooth disease type 4F Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Charcot-Marie-Tooth disease type 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change replaces valine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 525 of the PRX protein (p.Val525Ala). This variant is present in population databases (rs149715830, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with clinical features of PRX-related conditions (PMID: 24627108, 26392352, 32376792). ClinVar contains an entry for this variant (Variation ID: 242179). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The alanine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 30, 2024 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at